OBJECTIVES: Right ventricular (RV) failure complicating left ventricular assist device implantation is associated with increased mortality. Despite a lack of supporting evidence, venoarterial extracorporeal membrane oxygenation (ECMO) support is increasingly being used as an alternative to traditional temporary RV support. We report our institutional experience with ECMO-facilitated RV support after left ventricular assist device implantation.
INTRODUCTION
Left ventricular assist device (LVAD) implantation as a bridge to transplant or destination therapy is a standard treatment for patients with terminal heart failure [1] . Best results are achieved with non-pulsatile LVADs with current 1-and 2-year survival rates of 80% and 70%, respectively [2] . Worse survival rates are observed in biventricular assist device (BiVAD) therapy, especially with pulsatile devices (50% 1-year survival) [2] . Early right ventricular (RV) failure is a major driver of perioperative mortality affecting up to 30% of patients after LVAD implantation and necessitates mechanical RV support, despite optimal medical treatment in 4-6% of the patients [3] [4] [5] . Typical signs of RV failure are high central venous pressure, low cardiac output (CO) and low mixed venous saturation, despite optimized utilization of inotropes and selective pulmonary vasodilators [6] . The reported mortality rates for early postoperative RV failure are high and range from 40% to 50% [3, 7] .
Right heart dysfunction with high filling pressures accompanies venous congestion and leads to various postoperative complications that involve hepatic, renal and pulmonary function. It results in a higher risk for reoperations because of bleeding, need for renal replacement therapy or mechanical ventilation due to failing end organs [8, 9] .
The causes for RV failure are multifactorial, and their occurrence after LVAD implantation are therefore difficult to predict; reported risk factors include non-ischaemic aetiology of heart failure, higher grade preoperative tricuspid insufficiency and changes in the geometry of the RV [10, 11] .
Various treatment strategies have been developed to overcome the dismal prognosis of perioperative right heart failure, refractory to maximal conservative treatment. These include primary BiVAD implantation (pulsatile or continuous flow) and different forms of temporary RV support extracorporeal membrane oxygenation (ECMO) implantation [3, 4, 7, 12, 13] . Temporary right ventricular assist device (RVAD) support is probably the most widely used option to support the RV in case of perioperative RV failure and is usually established by the central or peripheral inflow cannulation and graft-facilitated outflow cannulation to the pulmonary artery, which also enabled awake, bedside explantation [3, 4] . By adding an oxygenator to the circuit, this set-up also allows for pulmonary support [4] . Recently, minimally invasive techniques for temporary RVAD implantation have even been described, which seem to improve outcomes [14, 15] . While primary and temporary RVAD implantation directly supports the right ventricle, ECMO implantation stabilizes systemic perfusion by adding additional perfusion, thereby allowing for gradual RV recovery [16] . All 3 strategies have been reported in small-to-medium size series, but have not been subjected to a randomized or even prospective non-randomized comparison [3, 4, 7, 12, 13, 15, [17] [18] [19] [20] . Results with all 3 approaches highly differ throughout the literature, with mortality rates consistently and significantly higher when compared with isolated LVAD implantation. Current short-to medium-term survival rates were in the range of 59% to 61% for primary BIVAD implantation range [2, 12, 13, 19] , 30% to 60% for temporary RVAD implantation [3, 4, 14] and 30% to 60% for ECMO-facilitated RV support [4, 7] . The wide range of results may best be explained by different thresholds for RVAD implantation and also reflect individual institutional experiences [3, [12] [13] [14] Overall, the suboptimal results currently reported with various options for RV support in the setting of perioperative RV failure after LVAD implantation warrant a thorough examination of this topic to improve future results.
We report our institutional experience with temporary venoarterial ECMO-facilitated RV support for perioperative RV failure in LVAD patients. 
MATERIALS AND METHODS

Study population
Indications for extracorporeal membrane oxygenation-facilitated right ventricular support
The decision for ECMO support was intraoperative in all patients. According to our institutional standards, ECMO support was indicated if the patient fulfilled the following criteria at the time of weaning from cardiopulmonary bypass (CPB) or in the postbypass period before leaving the operating room: (i) the need for more than 8 lg/kg/min of dobutamine plus levosimendan to achieve a mixed venous saturation of more than 60% using the full range of conservative treatment options to lower pulmonary artery pressures (i.e. inhaled nitric oxygen and normal to hypocapnic ventilation), (ii) the need for excessive use of vasopressors (vasopressin plus noradrenalin), (iii) poor contractility of the RV upon visual inspection (not applicable in minimally invasive cases) or transoesophageal echocardiography (TOE) and (iv) developing metabolic disorders (increase in lactate levels) and secondary organ damage (if not already pre-existing).
Extracorporeal membrane oxygenation
ECMO circuit and cannulation techniques have been described in detail before [21] . Briefly, the circuit consisted of a centrifugal pump (usually BPX-80 Bio-Pump V R , Medtronic Inc., Minneapolis, MN, USA) and a hollow fibre microporous membrane oxygenator (Affinity NT V R , Medtronic Inc.) with integrated heat exchanger. There was a switch to a plasma tight membrane oxygenator (Maquet Quadrox) in case of plasma leakage. Anticoagulation during ECMO was performed with intravenous heparin [target Activated Partial Thromboplastin Time (aPTT) 60-70 s]. According to our institutional standards, ECMO cannulation was preferentially performed via the subclavian artery (side graft, cannula size 17-21 Fr) and femoral vein (percutaneously, cannula size 19-21 Fr). Alternatively, percutaneous cannulation of the femoral artery and vein was performed. In case of the subclavian approach, bilateral radial artery monitoring was installed and a rubber band was placed distally to the anastomosis, which could then be tightened if the blood pressure difference became evident to prevent overflow to the cannulated arm.
Balancing extracorporeal membrane oxygenation and left ventricular assist device flow
For optimal haemodynamic support and LVAD function, ECMO and LVAD flows should be balanced as the 2 devices can compete if set inappropriately. We achieved this by adjusting ECMO and LVAD flows at the time of CPB weaning under continuous TOE control. The general goals were: (i) decompression of both ventricles, (ii) a neutral to rightwards septum position and (iii) avoidance of suction. In case of haemodynamic instability or at the time of flow changes, TOE or TTE had to be repeated in the intensive care unit (ICU).
Protocol for weaning off extracorporeal membrane oxygenation and criteria for right ventricular recovery
During ECMO, all patients were monitored by a Swan-Ganz catheter. ECMO flow was gradually reduced as soon as an RV output of at least 2.5 l/m 2 body surface area was observed. If the patient tolerated a flow of 1.5 l/min over a period of 12 h without increasing catecholamine support, ECMO was explanted. Because there were no reliable echo criteria for weaning off ECMO, this decision was mainly based on clinical judgement.
Outcome measures
Primary end-points were: (i) development of haemodynamic parameters, (ii) 30-day mortality and in-hospital mortality and (iii) 1-year survival or bridge to transplant success.
Secondary end point was the development of renal and hepatic function.
Haemodynamic parameters were obtained from preoperative right heart catheterizations and/or pulmonary artery catheter data while monitored in the ICU.
Statistical analysis
Categorical variables were presented as numbers and percentages, and mean values and standard deviations were determined for continuous variables. Comparison of means was performed using the paired t-test or Wilcoxon test, when appropriate. A P-value of < 0.05 was considered statistically significant. Survival was determined using the Kaplan-Meier method.
The IBM SPSS software version 21 (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis.
RESULTS
Patient characteristics
Thirty-two patients (84.4% male; mean age 52 ± 14 years; age range 16-70 years) received ECMO for temporary RV support after LVAD (HMII LVAD 25%, HVAD 75%) implantation from May 2009 to April 2014. Heart failure was of dilative in 50%, ischaemic in 40.6% and other origin in 9.4% (myocarditis in 1 patient and post-cardiotomy syndrome in 2 patients) of patients. At the time of LVAD implantation, 71.8% of the patients were in INTERMACS Level I, 6.3% in INTERMACS Level II, 12.5% in INTERMACS Level III and 9.4% in INTERMACS Level IV-VII. Eighteen (56.3%) patients were preoperatively already intubated for more than 24 h, and 7 (21.9%) patients needed haemofiltration. Most patients (71.8%) were on high inotropic support before LVAD implantation. Detailed patient characteristics are given in Table 1 .
Operative procedure VAD implantation was performed via either a full median sternotomy (56.3%) or a bilateral thoracotomy (43.7%). Circulatory support during VAD implantation was provided by standard CPB in 53.1% and ECMO in 43.8%, and 1 patient underwent off-pump implantation. In 93.8% of patients, the decision for temporary ECMO support was made while weaning from CPB, and in 2 patients RV dysfunction became obvious after initial successful weaning from CPB but before leaving the operating room. No patient needed a permanent RVAD. Additional procedures (aortic valve replacement 3.1%, tricuspid valve repair 25% and replacement of the ascending aorta 3.1%) were performed in 28.1% of the patients and delayed sternal closure in 15.6% of patients. Using TOE, the 2 circuits (ECMO and LVAD) were balanced, with the goal to reach a decompression of both ventricles without suction and without shifting of the interventricular septum. The detailed results are given in Table 2 .
Haemodynamic parameters during extracorporeal membrane oxygenation
Central venous pressure was 13 ± 3 mmHg before LVAD implantation, and mean pulmonary artery pressure was 28 ± 6 mmHg. The mean CO was 5.1 ± 1.3 l/min. In all patients, a significant improvement in haemodynamics was observed (central venous pressure 9 ± 4 mmHg, P = 0.01; mean pulmonary artery pressure 21 ± 10 mmHg, P = 0.04; CO 5.9 ± 2.3 l/min, P = 0.09) during ECMO support.
Development of end-organ function during extracorporeal membrane oxygenation
Renal function. All patients had laboratory (creatinine 1.73 ± 1.08 mg/dl) and/or clinical signs (typically anuria) of renal dysfunction before LVAD implantation, with 7 (21.9%) patients already depending on venovenous haemofiltration. ECMO improved renal function (creatinine 1.14 ± 0.78 mg/dl, P = 0.05) over a median period of 3 days 1-15 days) . However, bilirubin levels were slightly increased after ECMO (3.74 ± 4.49 mg/dl, P = 0.01). We observed no fulminant postoperative liver failures in this series.
All assessed clinical parameters are given in Table 3 .
Outcomes
Perioperative bleeding and thromboembolic complications.
Two (6.3%) patients suffered an ischaemic stroke on postoperative days (PODs) 3 and 14, respectively, 1 of whom with fatal consequences (POD 3). Significant perioperative bleeding requiring surgical revision occurred in 6 (18.8%) patients, including pericardial bleeding (9.4%), haemothorax (6.3%) and retroperitoneal haematoma (3.1%).
One patient suffered a haemorrhagic stroke (POD 23) with fatal consequences.
Outcome while on left ventricular assist device and temporary right ventricular support. Median duration of postoperative RV support was 3 days (1-15 days). ECMO-related complications occurred in 21.9% of patients, including thromboembolism (10%) requiring thrombectomy in 1 patient, significant haemolysis (6.3%), vascular complications with the need for reconstruction of the femoral artery (3.1%) and lymph fistula in the groin (3.1%). Three patients (9.4%) died while on LVAD and ECMO support, due to sepsis (POD 2), multiorgan dysfunction syndrome (POD 11) and ischaemic stroke (POD 3). All survivors (90.6%) could be successfully weaned from ECMO support.
Outcome after weaning from right ventricular support.
In-hospital stay was 37 ± 30 days after LVAD implantation. Two more ischaemic strokes occurred on POD 84 and POD 584, respectively. One patient experienced a pump thrombus and underwent successful intravenous lysis (POD 224).
After a follow-up period of 1-year, 15 (46.9%) patients were still on device, 8 (25%) patients were successfully transplanted, 8 (25%) patients died on LVAD support and 2 (6.3%) patients could be weaned from long-term LVAD support. The reasons for death were multiorgan dysfunction syndrome (50%), sepsis (25%), haemorrhagic stroke (12.5%) and ischaemic stroke (12.5%). Details are given in Table 4 .
Overall, 30-day and in-hospital mortality were 18.8% (n = 6) and 25% (n = 8), respectively. One-year survival was 75% (n = 24) and is depicted in Fig. 1 .
COMMENT
Right heart failure is a frequent complication after LVAD implantation that is associated with high morbidity and mortality. Despite optimized medical management, a significant number of LVAD patients need some sort of perioperative mechanical right heart support. We demonstrate the appropriateness of ECMO for perioperative right heart support in a variety of clinical scenarios including minimally invasive LVAD implantations.
Right heart failure affects between 16% and 28% of patients undergoing LVAD implantation [3, 4] . The causes for RV failure are multifactorial and relate to perioperative and anatomical factors, such as changes in RV geometry and haemodynamics as response to left ventricular unloading or significant preoperative tricuspid valve regurgitation [11, 22] . Strategies to prevent and treat perioperative right heart failure include optimization of LVAD speed, inotropic therapy and the use of selective pulmonary vasodilators [8] . Despite the growing experience with RV management, a certain proportion of patients will need temporary mechanical RV In-hospital stay (days), mean ± SD 37 ± 30 ICU stay (days), mean ± SD 26 ± 23 Intermittent haemofiltration, n (%) 12 (41.4) Duration (days), mean ± SD 7 ± 13 Duration of intubation (days), mean ± SD 9 ± 6 Major bleeding, n (%) Pericardial 3 (9. support to ensure adequate end-organ perfusion after LVAD implantation [8] . Currently, different management strategies are employed to support the right ventricle after LVAD implantation. Primary BiVAD or total artificial heart implantation is an obvious option, which has undergone a renaissance with first reports of permanent continuous-flow BiVAD implantation with the HVAD and the recently developed HM 3 system [12, 23] . The benefit of this approach is a durable long-term support of the RV. Survival rates with continuous-flow BiVADs have only been reported in small series and range from 59% to 61% after only several months of support [2, 12, 13, 19] . No larger registries have been published so far. Additionally, this approach is limited by several factors including the lack of dedicated controllers, the need for 2 drivelines and 2 sets of controller/battery packs and the lack of a Conformité e Europé enne (CE)-marking and Food and Drug Administration (FDA) approval. Given the limitations of permanent BiVADs, the majority of institutions continue to pursue a strategy of temporary RV support and eventual isolated LVAD support after RV recovery to overcome the limitations of permanent BiVADs. Currently, 2 different options of temporary RV support are used. The first option is typical implantation of a temporary RVAD, usually a centrifugal pump with cannulation of the main pulmonary artery and the right atrium [17] . If implanted in this configuration, explantation necessitates reopening of the chest, which is a major disadvantage. However, minor modifications to the implant technique with graft cannulation of the pulmonary artery and percutaneous inflow cannulation allow for awake bedside explantation [3, 4] . Even minimally invasive implantation of temporary RVADs is feasible nowadays. The main advantages of temporary RVADS are: (i) the classic RVAD set-up with no risk of systemic thromboembolism and (ii) no flow competition between RVAD and LVAD. The main disadvantages include: (i) the pulmonary artery has to be cannulated and decannulated at the time of RVAD explant, (ii) the potential for pulmonary overflow and 'RVAD-induced' pulmonary oedema and (iii) the need for ECMO explantation and RVAD implantation in patients who are on ECMO preoperatively. Reported survival rates are similar to those achieved with permanent BiVAD implantation, reaching up to 60% [7] . However, these techniques, despite being extremely attractive, have only been described in case reports and small case series, and the published evidence currently does not support any definite conclusion [4, 15, 18, 20] . The same is true for the Impella RV pump, which is designed for percutaneous RVAD support and might become the standard temporary RVAD if it fulfils the high expectations and does not put the tricuspid valve, which has to be passed through by a significantly-sized catheter, at risk. In contrast to temporary RVADs, multiple groups use ECMO systems as temporary RV support. Despite the fact that ECMO support does not fulfil the definition of a temporary RVAD, the haemodynamic effects are similar as the total CO is increased and the workload for the RV is reduced. The main criticism for this approach is that overall LVAD flow is typically not increased and that the ECMO and LVAD system 'compete' with each other [4] . Nevertheless, ECMO has several profound advantages. ECMO not only provides additional CO, thereby improving end-organ perfusion, it can additionally improve oxygen delivery and lung support, which can be advantageous, especially in patients in advanced INTERMACS levels. Furthermore, ECMO can easily be implanted in a bedside fashion, should the necessity for temporary support only become obvious after the implant procedure and can be explanted with the same ease in the ICU on an awake and commonly extubated patient. ECMO can also be facilitated for temporary support in patients after sternotomy sparing LVAD implantation, as cannulation of the main pulmonary artery is not necessary.
ECMO for temporary RV support was successful in 29 (90.6%) patients. The 3 cases of weaning failures did not occur due to poor RV function but were mainly caused by ECMO-related complications, sepsis and stroke. With our strategy we could achieve an excellent 1-year survival of 74% (24 patients) within this severely ill patient cohort that comprises 71.8% INTERMACS Level 1 patients. The rate of adverse events was-as expected-not negligible and higher than in isolated LVAD implantation. One of the main limitations of ECMO support for RV failure lies within the fact that the complication rate increases with increasing duration of support [24] . ECMO-related complications occurred in almost one-quarter of the patients (21.9%) in this cohort and included thromboembolism (10%), significant haemolysis (6.3%), vascular complications with the need for reconstruction of the femoral artery (3.1%) and lymph fistula in the groin (3.1%). Perioperative thromboembolic complications occurred in 2 patients, and significant perioperative bleeding events were observed in 6 (18%) patients. These complication rates, however, do not differ much from those reported by other groups using temporary RVAD with pulmonary artery cannulation. Bleeding requiring revision occurred in 38-60%, cerebral haemorrhage in up to 16% and ischaemic stroke in up to 22%, whereas we observed these cerebrovascular accidents in only 4.5% and 12.5.%, respectively [3, 4] .
Our reported series of 32 patients with temporary ECMO support for RV failure after LVAD implantation is one of the largest consecutive patient series so far and represents an institutional approach to resolve a typical post-LVAD problem. Of note, the results obtained with ECMO for temporary RV support obtained in this cohort with a 1-year survival of 74% is at least comparable to previous reports on temporary and permanent mechanical RV support in comparable patients with 6-month survival rates of only 50-60% [3, 4, 7, 12] . Importantly, we observed no late right heart failures. However, the complication rate for peripheral ECMO, especially in terms of thromboembolic events, seems to be slightly higher than the one reported for the true RVAD group with cannulation of the pulmonary artery [3, 4] .
Limitations
Although data were obtained from a registry, this study has the typical limitations of a retrospective analysis. The population is not uniform in terms of aetiology and era of implantation, there might be better overall outcomes in coming studies, considering recent improvements in intensive care and surgical techniques. Furthermore, the study is limited by the lack of a standard temporary RVAD control group.
CONCLUSION
The development of early RV failure in LVAD recipients is a major driver of perioperative mortality. Temporary ECMO-facilitated RV support is associated with good long-term outcomes and high rates of RV recovery.
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